Tests LY4247147 for safety in healthy adults with obesity or overweight
Tests LY4247147 in healthy adults with obesity or overweight, checking safety first.
Plain-language title generated from the registry record
Registry title: A Study of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Key facts
- Where
- Lenexa and Salt Lake City, United StatesSee the 2 sites
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07915245, who can take part
Where in United States
- ICON Early Phase Services Lenexa CenterLenexa, United StatesNo longer taking part
- ICONSalt Lake City, United StatesNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07915245
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it.Read full original descriptionShow less
A Phase 1, Randomized, Placebo-Controlled, Single- and Multiple-Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY4247147 in Participants With Obesity or Overweight Who Are Otherwise Healthy
The main purpose of this study is to understand how safe and well-tolerated LY4247147 is in participants with obesity or overweight who are otherwise healthy. Blood tests will be performed to check how much LY4247147 gets into the bloodstream and how long it takes the body to eliminate it.
The study will be conducted in 3 parts. For each participant in Parts A and C, the study will last about 30 weeks and will include a stay in the Clinical Research Unit (CRU) lasting about 8 nights. For each participant in Part B, the study will last about 39 weeks and will include up to 3 stays in the CRU lasting about 9 nights each.
Inclusion: Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease; Have overweight with a BMI of greater than or equal to (≥) 27 kilograms per square meter (kg/m²); Have obesity with a BMI of ≥30 kg/m2; Have had a self-reported stable weight for 3 months prior to screening; Singapore only: Participants must be 21 to 65 years of age.
Exclusion: Have a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data; Is an individual of childbearing potential (IOCBP).